Nebulized Long-Acting Muscarinic Antagonists (Lonhala Magnair, Yupelri)
Cigna coverage policy for formulary exceptions and medical necessity review for nebulized LAMA products Lonhala Magnair (glycopyrrolate) and Yupelri (revefenacin) for long-term maintenance treatment of COPD in adults.
No material clinical or coverage changes in this update.
Coverage Summary
Coverage stance: covered_with_criteria — Nebulized LAMA products Lonhala Magnair (glycopyrrolate) and Yupelri (revefenacin) are covered with medical necessity criteria for long‑term maintenance treatment of COPD in adults, per the policy scope. Scope: formulary exceptions and medical necessity review for these nebulized LAMA products for long‑term maintenance COPD treatment in adults. Key facts: • Minimum age: 18+. • Initial authorization duration (max): 12 months.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.